<DOC>
	<DOCNO>NCT01742286</DOCNO>
	<brief_summary>The purpose study estimate maximum tolerate dose and/or recommend dose expansion LDK378 single agent , assess safety , tolerability anti-tumor activity characterize single multiple-dose pharmacokinetics administer orally pediatric patient ALK-activated tumor , without food .</brief_summary>
	<brief_title>Phase I Study LDK378 Pediatric , Malignancies With Genetic Alteration Anaplastic Lymphoma Kinase ( ALK )</brief_title>
	<detailed_description>LDK378 novel inhibitor ALK active broad range ALK-activated tumor model , include model driven mutate version ALK know resistant crizotinib , ALK gene amplification . The primary purpose study determine maximum tolerate dose and/or recommend dose expansion pediatric patient , delineate clinical dose use future pediatric study , without food . This study also assess safety , tolerability , PK preliminary evidence antitumor activity LDK378 pediatric patient neuroblastoma , ALK-activated tumor .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Diagnosed locally advanced metastatic malignancy progress despite standard therapy , effective standard therapy exist Age â‰¥ 12 month &lt; 18 year The tumor must carry genetic alteration ALK Patients must evaluable measurable disease Exclusion criterion : Symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid local CNSdirected therapy ( radiotherapy , surgery intrathecal chemotherapy ) control CNS disease Clinically significant , uncontrolled heart disease Inadequate end organ function define specified laboratory value Use medication know strong inhibitor inducer CYP3A4/5 discontinue least 1 week prior start treatment LDK378 duration study Use medication mainly metabolize CYP3A4/5 CYP2C9 discontinue least 1 week prior start treatment LDK378 duration study . History interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis History pancreatitis history increase amylase lipase due pancreatic disease . Medications know risk prolongation QT interval Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pediatric , anaplastic lymphoma kinase , ALK-activated tumor , neuroblastoma , rhabdomyosarcoma , anaplastic large-cell lymphoma , inflammatory myofibroblastic tumor</keyword>
</DOC>